Brief: Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran
08/04/2025 14:19
April 8 (Reuters) - Avidity Biosciences Inc RNA.O: AVIDITY BIOSCIENCES RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN FOR DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AVIDITY BIOSCIENCES INC - EXPECTS TO COMPLETE PHASE 3 HARBOR STUDY ENROLLMENT IN MID-2025 Source text: ID:nPn1rjtTba Further company coverage: RNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off